These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 544474)

  • 21. Natural cell-mediated cytotoxicity in Ehrlich ascites tumor-bearing mice.
    Olinescu A; Hristescu S; Mazilu E
    Neoplasma; 1983; 30(2):147-52. PubMed ID: 6843720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of neuraminidase in experimental immunotherapy of two murine pulmonary carcinomas.
    Alley CD; Snodgrass MJ
    Cancer Res; 1977 Jan; 37(1):95-101. PubMed ID: 830425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas.
    Simmons RL; Rios A
    J Immunol; 1973 Dec; 111(6):1820-5. PubMed ID: 4750868
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibody formation for malignant tumor. 3. Antigenicity of peptide of ribosomal digest in Ehrlich ascites tumor.
    Yamamoto Y; Jituiki D; Yabuki Y
    Acta Med Okayama (1952); 1970 Oct; 24(5):534-7. PubMed ID: 4256472
    [No Abstract]   [Full Text] [Related]  

  • 25. Studies on anti-tumor immunity. I. Homologous immunity against Ehrlich ascites tumor (acquired type of immunity against tumor).
    Soeda M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1967 Mar; 26(12):1598-608. PubMed ID: 5232509
    [No Abstract]   [Full Text] [Related]  

  • 26. BCG versus VCN: the antigenicity and the adjuvant effect of both compounds.
    Seiler FR; Sedlacek HH
    Recent Results Cancer Res; 1980; 75():53-60. PubMed ID: 7232840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study on transplantation immunity of Ehrlich ascites tumor and methylcholanthrene-induced tumor in mice, with special reference to local immunity of lymph nodes draining the site of sensitization.
    Kitano M; Okada Y
    Bull Chest Dis Res Inst Kyoto Univ; 1968 Mar; 1(1):1-17. PubMed ID: 5678190
    [No Abstract]   [Full Text] [Related]  

  • 28. Suppression of Ehrlich ascites tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype of the anti-GT1b IgM.
    Saha S; Mondal S
    Indian J Exp Biol; 2000 Dec; 38(12):1207-16. PubMed ID: 11411041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance and susceptibility to tumours. IV. The temporary survival and rejection of the Ehrlich ascites carcinoma in xenogeneic hosts.
    Dvorák R; Karásek J
    Neoplasma; 1970; 17(4):361-71. PubMed ID: 4394171
    [No Abstract]   [Full Text] [Related]  

  • 30. Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin.
    Buzzi S; Buzzi L
    Cancer Res; 1974 Dec; 34(12):3481-6. PubMed ID: 4429964
    [No Abstract]   [Full Text] [Related]  

  • 31. Resistance and susceptibility to tumours. VI. Reaction of labelled lymphoid cells transferred into the site of previously implanted carcinoma.
    Dvorák R; Lindner J
    Neoplasma; 1971; 18(1):63-86. PubMed ID: 5575435
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of Ehrlich ascites tumor growth by nucleoprotein. II. In vivo fate of the tumor cells.
    Bradshaw LJ; Webb DR
    J Natl Cancer Inst; 1969 Sep; 43(3):527-32. PubMed ID: 4980604
    [No Abstract]   [Full Text] [Related]  

  • 33. [The modelling of the growth of Ehrlich carcinoma and teratoma T-36 with ascitic fluid and tumor-cell dialysate].
    Donenko FV; Kabieva AO; Moroz LV
    Biull Eksp Biol Med; 1992 Jul; 114(8):193-5. PubMed ID: 1467492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The morphofunctional characteristics of lymphoma NK/LY cells treated with concanavalin A and Vibrio cholerae neuraminidase].
    Bratus' GG; Naumenko OI; Nastenko EP; Novichenko NL
    Tsitologiia; 1990; 32(1):67-73. PubMed ID: 2375060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor resistance formation in animals in early neonatal period.
    Kazmin SD; Todor IN; Chekhun VE
    J Exp Clin Cancer Res; 2007 Mar; 26(1):83-90. PubMed ID: 17550136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuraminidase treated cells and their role in cancer immunotherapy.
    Simmons RL; Rios A
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):223-8. PubMed ID: 4611534
    [No Abstract]   [Full Text] [Related]  

  • 37. Influence of Ehrlich ascites carcinoma on repopulating ability of mouse bone marrow cells.
    Clerici E; Mocarelli P; Villa ML; Natale N
    J Natl Cancer Inst; 1971 Sep; 47(3):555-60. PubMed ID: 4945589
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune reactions in Ehrlich ascites tumour-bearing mice.
    Olinescu A; Babeş S; Piţur I
    Arch Roum Pathol Exp Microbiol; 1980; 39(3):249-57. PubMed ID: 7018456
    [No Abstract]   [Full Text] [Related]  

  • 39. Studies on anti-tumor immunity. II. Studies on inhibitory effect of heterologous spleen cells on the growth of Ehrlich ascites tumor.
    Soeda M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1967 Mar; 26(12):1609-16. PubMed ID: 5232510
    [No Abstract]   [Full Text] [Related]  

  • 40. [The effect of ascitic fluid on the growth of Ehrlich tumor and Lewis carcinoma].
    Donenko FV; Kabieva AO; Moroz LV
    Biull Eksp Biol Med; 1992 Jul; 114(8):191-3. PubMed ID: 1467491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.